Aspire Biopharma Holdings, Inc.
ASBP
$0.4871
-$0.0205-4.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 235.60K | 86.40K | 153.40K | 65.80K | 50.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.60K | 96.90K | 163.90K | 76.30K | 65.50K |
| Operating Income | -242.60K | -96.90K | -163.90K | -76.30K | -65.50K |
| Income Before Tax | -242.60K | -96.90K | -163.90K | -76.30K | -65.50K |
| Income Tax Expenses | 1.00K | -- | -- | 500.00 | -- |
| Earnings from Continuing Operations | -243.60K | -96.90K | -163.90K | -76.80K | -65.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -243.60K | -96.90K | -163.90K | -76.80K | -65.50K |
| EBIT | -242.60K | -96.90K | -163.90K | -76.30K | -65.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Basic EPS | 0.00 | 0.00 | -- | 0.00 | -- |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Diluted EPS | 0.00 | 0.00 | -- | 0.00 | -- |
| Average Basic Shares Outstanding | 443.32M | 443.32M | -- | 443.00M | -- |
| Average Diluted Shares Outstanding | 443.32M | 443.32M | 443.00M | 443.00M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |